Results 161 to 170 of about 596,047 (352)

Harnessing Synergies between Combinatorial Microfluidics and Machine Learning for Chemistry, Biology, and Fluidic Design

Chemistry–Methods, EarlyView.
This review explores the synergy of combinatorial microfluidics and machine learning, highlighting their transformative impact on high‐throughput experimentation, closed‐loop reaction optimization, and autonomous platform development. Key applications in chemical synthesis, biological research, and microfluidic design are discussed, addressing ...
Suyash S. Damir, Julie Probst, Andrew deMello, Stavros Stavrakis   +3 more
wiley   +1 more source

Urinary tract infection in infancy. [PDF]

, 1968
Paul O’Neill, C. G. H. Newman
openalex   +1 more source

Urinary Tract Infection [PDF]

Journal of Clinical Pathology, 1983
openaire   +3 more sources

Safety and Pharmacokinetics of Long‐Acting Monoclonal Antibodies Tixagevimab and Cilgavimab (AZD7442) in a China Phase 2 Study and Evaluation of Asian Race Effect

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Safety, pharmacokinetics, and impact of race of pharmacokinetics on monoclonal antibodies tixagevimab and cilgavimab (AZD7442) were assessed in Chinese adult participants in a Phase 2, randomized, double‐blind, placebo‐controlled trial. In total, 272 participants were randomized 3:1 to a single intravenous dose of 600 mg AZD7442 or placebo and
Jing Zhang, Huixia Zhang, Yajuan Zhang, Shuyuan Liu, Xiaoyun Ge, Haiyue Zhang, Yunfei Li, Cecil Chi‐Keung Chen, Oleg Stepanov, Weifeng Tang, Wenhong Zhang   +10 more
wiley   +1 more source

Cefdinir Versus Cephalexin for the Treatment of Uncomplicated Urinary Tract Infections. [PDF]

Open Forum Infect Dis
Mitzner TM, Eid KM, Hughson DM, Jameson AP, Dumkow LE.   +4 more
europepmc   +1 more source

Pharmacokinetics, Tolerability, and Biomarker Profile of the Neurokinin 3 Receptor Antagonist Fezolinetant in Healthy Japanese Individuals: A 2‐Part, Randomized, Phase 1 Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract This 2‐part, randomized, placebo‐controlled, double‐blind, Phase 1 study analyzed the pharmacokinetics, safety, and biomarker profile of fezolinetant in healthy Japanese individuals. Part 1: male participants received single doses of placebo or fezolinetant 15 or 60 mg.
Akira Koibuchi, Megumi Iwai, Kanji Komatsu, Kentaro Kuroishi, Mai Shibata, Masako Saito, Jace Nielsen, Jiayin Huang, Shunji Matsuki   +8 more
wiley   +1 more source

The rising threat of antibiotic and multidrug resistance in neonatal urinary tract infections. [PDF]

BMC Pediatr
Sağlam MK, Yanaşoğlu E, Sav NM, Kurt F, Kocabay K, Akbaş E, Sungur MA.   +6 more
europepmc   +1 more source

Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Asciminib is the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP) in patients with chronic myeloid leukemia. This phase 1, two‐treatment‐period, drug‐drug interaction study evaluated the effect of steady‐state asciminib on the pharmacokinetics of atorvastatin.
Matthias Hoch, Wendy Weis, Felix Huth, Seshulatha Jamalapuram, Michelle Quinlan, Amarnath Bandaru, Suleyman Eralp Bellibas, Asmae Mirkou, Shruti Kapoor, Shefali Kakar   +9 more
wiley   +1 more source

Trichosporon Urinary Tract Infections: A Hidden Menace Revealed. [PDF]

Iran J Pathol
Elmimoghaddam A, Vahidi M, Heidari R, Ghorbani M, Aslani P.   +4 more
europepmc   +1 more source

Risk of Infections with SGLT2 Inhibitors Versus DPP4 Inhibitors: A Population‐Based Cohort Study Using Antibiotic Dispensing Data

Clinical Pharmacology &Therapeutics, EarlyView.
This study compared the number and cumulative dose of antibiotic dispensings among new users of sodium–glucose cotransporter‐2 (SGLT2) inhibitors and dipeptidyl peptidase‐4 (DPP4) inhibitors following hospital discharge in individuals with type 2 diabetes.
Maria J. Alfonso Arvez, George S. Q. Tan, Sam Wade, Zanfina Ademi, Jenni Ilomäki, J. Simon Bell   +5 more
wiley   +1 more source